北京深蓝海生物医药科技

Beijing Deep Blue Sea Biopharmaceutical Technology (DBS) is a leading Chinese Contract Research Organization (CRO) specializing in clinical research services for the pharmaceutical and medical device industries. As a key subsidiary of Tigermed, the company provides end-to-end solutions including clinical trial management (Phase I-IV), regulatory affairs, bioequivalence (BE) studies, data management, and biostatistics. DBS is recognized for its extensive experience in navigating the National Medical Products Administration (NMPA) regulatory landscape and executing high-quality clinical trials to support both domestic and international drug development. The company leverages its deep local expertise and Tigermed's global network to accelerate the market entry of innovative therapies.